Adjuvant Therapy
Durvalumab regimen improves outcomes in muscle-invasive bladder cancer
Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.
Gene signature predicts severe adverse events from ICI therapy for melanoma
Researchers identified a gene signature that can predict which group of patients with melanoma will experience severe immune-related adverse events when treated with immune checkpoint inhibitor therapy, according to a study.
Chemotherapy regimen improves survival in advanced esophageal cancer
CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Keytruda extends survival in high-risk triple negative breast cancer
A study assessing the efficacy of pembrolizumab met a key secondary endpoint of extending OS, in combination with chemotherapy, among patients with high-risk early-stage triple-negative breast cancer, according to the agent’s manufacturer.
'Immense' change prompts new guideline to address salvage therapy for prostate cancer
The American Urological Association released a clinical practice guideline pertaining to salvage therapy for men with prostate cancer.
New data support 'potentially practice-changing' approach to sentinel lymph node biopsy
Sentinel lymph node biopsy may be omitted in certain patients with early-stage breast cancer, according to findings presented at American Society of Breast Surgeons Annual Meeting.
Some men with breast cancer may have higher mortality risk
Like women, men with hormone receptor-positive breast cancer have mortality risks that persist 20 years after diagnosis, with age, tumor size and grade, and nodal status playing factors, according to findings published in JAMA Oncology.
Pembrolizumab after surgery shows ‘practice changing’ survival benefit for kidney cancer
Adjuvant therapy with pembrolizumab following nephrectomy conferred significant improvement in OS compared with placebo among adults with renal cell carcinoma who had a high risk for disease recurrence, study results showed.
Study: White bread, alcohol may increase risk for colorectal cancer
Consuming high amounts of white bread and alcohol were linked to an increased risk for colorectal cancer, a recent study in Nutrients showed. Meanwhile, fiber, magnesium and other dietary components were associated with a reduced risk.